Latest Breaking News On - Bio thera solutions ltd - Page 2 : comparemela.com

FDA Approves Bio-Thera Solutions Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

FDA Approves Bio-Thera Solutions Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLi zhangShengfeng liWechat bio theraBiogen incGenentech incBio thera solutionsDrug administrationPrnewswire bio thera solutions ltdBio thera solutions ltdBio thera solutionThera solutionsUnited states food

FDA Approves Bio-Thera Solutions Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug Administration.

United statesLi zhangWechat bio theraShengfeng liGenentech incBiogen incPrnewswire bio thera solutions ltdBio thera solutions ltdBio thera solutionsDrug administrationBio thera solution avziviBio thera solutionThera solutionsUnited states food

Bio-Thera Solutions Announces Positive Results From Phase 3 Study Of BAT2206, A Proposed Biosimilar Referencing Stelara®

Bio-Thera Solutions Announces Positive Results From Phase 3 Study Of BAT2206, A Proposed Biosimilar Referencing Stelara®
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Amin zhengUnited statesShengfeng liWechat bio theraJanssen stelaraBio thera solutions announces positivePrnewswire bio thera solutions ltdCongratulations to bio thera solutionsBiogen incBio thera solutionsJohnson corporationBio thera solutions ltdThera solutionsPsoriasis areaSeverity indexThera solutions announces positive results

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara®

/PRNewswire/ Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets,.

United statesAmin zhengShengfeng liJanssen stelaraWechat bio theraCongratulations to bio thera solutionsBio thera solutionsBio thera solutions ltdBiogen incPrnewswire bio thera solutions ltdJohnson corporationThera solutionsPsoriasis areaSeverity index

FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA® developed by Bio-Thera Solutions

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, announced that its partner Biogen recently received notification from the United States Food and Drug Administration (FDA) on the approval of TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheuma

Hong kongUnited statesWechat bio theraShengfeng liBiogen incBio thera solutionsBio thera solutions ltdDisease modifying anti rheumatic drugsJuvenile idiopathic arthritisImportant safety informationThera solutionsRheumatoid arthritisJuvenile idiopathic arthritisPharmaceutical companyMonoclonal antibodyDbio thera